Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research note published on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued research reports about the company. Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and increased their price objective for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. JPMorgan Chase & Co. lifted their price target on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Finally, Needham & Company LLC restated a “hold” rating and set a $100.00 price objective on shares of Intra-Cellular Therapies in a research report on Monday, January 13th. Nine equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Intra-Cellular Therapies has a consensus rating of “Moderate Buy” and a consensus target price of $103.62.

Intra-Cellular Therapies Stock Down 0.2 %

Shares of ITCI opened at $127.82 on Friday. The business has a 50-day simple moving average of $105.80 and a two-hundred day simple moving average of $88.04. The stock has a market cap of $13.59 billion, a price-to-earnings ratio of -146.92 and a beta of 0.72. Intra-Cellular Therapies has a 52 week low of $62.78 and a 52 week high of $128.19.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $91,834,228.20. The trade was a 4.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.60% of the company’s stock.

Institutional Trading of Intra-Cellular Therapies

Institutional investors and hedge funds have recently modified their holdings of the stock. Norges Bank purchased a new position in shares of Intra-Cellular Therapies during the fourth quarter valued at $268,347,000. Raymond James Financial Inc. bought a new position in Intra-Cellular Therapies during the 4th quarter worth about $76,451,000. Adage Capital Partners GP L.L.C. increased its position in Intra-Cellular Therapies by 266.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 678,000 shares of the biopharmaceutical company’s stock valued at $56,627,000 after purchasing an additional 493,000 shares during the period. TimesSquare Capital Management LLC raised its holdings in shares of Intra-Cellular Therapies by 91.8% in the 4th quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company’s stock valued at $70,179,000 after purchasing an additional 402,186 shares in the last quarter. Finally, Eagle Asset Management Inc. lifted its position in shares of Intra-Cellular Therapies by 130.5% in the 3rd quarter. Eagle Asset Management Inc. now owns 624,759 shares of the biopharmaceutical company’s stock worth $45,714,000 after purchasing an additional 353,723 shares during the period. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.